These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 23040786

  • 21. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [Abstract] [Full Text] [Related]

  • 26. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG.
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [Abstract] [Full Text] [Related]

  • 28. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER, Siler T, Owen R, Kramer B.
    Int J Chron Obstruct Pulmon Dis; 2011 Dec; 6():431-8. PubMed ID: 22003288
    [Abstract] [Full Text] [Related]

  • 29. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 30. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

  • 31. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
    Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D.
    Am J Respir Crit Care Med; 2015 Nov 01; 192(9):1068-79. PubMed ID: 26177074
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May 01; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2016 May 01; 11():2543-2551. PubMed ID: 27785010
    [Abstract] [Full Text] [Related]

  • 34. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2017 May 01; 12():339-349. PubMed ID: 28176893
    [Abstract] [Full Text] [Related]

  • 35. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 36. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
    Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B.
    Allergol Int; 2010 Sep 14; 59(3):285-293. PubMed ID: 20567133
    [Abstract] [Full Text] [Related]

  • 37. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
    Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, INDORSE Study Investigators.
    Chest; 2011 Jul 14; 140(1):68-75. PubMed ID: 21349928
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 14; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 39. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM, Wagner F, Khindri S, Drollmann AF.
    COPD; 2011 Oct 14; 8(5):340-5. PubMed ID: 21793716
    [Abstract] [Full Text] [Related]

  • 40. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T.
    Thorax; 2010 Dec 14; 65(12):1086-91. PubMed ID: 20978028
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.